Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Antares Pharma, Inc.    ATRS


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Antares Pharma Inc : Pomerantz Law Reminds Shareholders with Losses on their Investment in Antares Pharma, Inc. of Class Action Lawsuit and Upcoming Deadline - ATRS

10/26/2017 | 06:26pm EST

NEW YORK, NY / ACCESSWIRE / October 26, 2017 / Pomerantz LLP announces that a class action lawsuit has been filed against Antares Pharma, Inc. ("Antares" or the "Company") (NASDAQ: ATRS) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and docketed under 17-cv-08945, is on behalf of a class consisting of investors who purchased or otherwise acquired Antares securities, seeking to recover compensable damages caused by defendants' violations of the Securities Exchange Act of 1934.

If you are a shareholder who purchased Antares securities between December 21, 2016, and October 12, 2017, both dates inclusive, you have until December 22, 2017, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

[Click here to join this class action]

Antares develops pharmaceutical delivery systems, including needle-free and mini-needle injector systems and transdermal gel technologies. The Company distributes its needle-free injector systems in various countries. Antares also conducts research and development with transdermal gel products and has several products in clinical evaluation with partners.

Antares's product Xyosted (originally known as QuickShot Testosterone or QST) has been among the Company's lead product candidates at all relevant times. Antares announced its submission of a New Drug Application ("NDA") for Xyosted to the U.S. Food and Drug Administration ("FDA") on December 21, 2016.

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Antares had provided insufficient data to the FDA in connection with its NDA for Xyosted; (ii) accordingly, Antares had overstated the approval prospects for Xyosted; and (iii) as a result of the foregoing, Antares' public statements were materially false and misleading at all relevant times.

On October 12, 2017, post-market, Antares disclosed that on October 11, 2017, the Company received a letter from the FDA stating that the agency had "identified deficiencies that preclude the continuation of the discussion of labeling and post marketing requirements/commitments" for Xyosted.

On this news, the Company's share price fell $1.41, or 37.80%, to close at $2.32 on October 13, 2017.

On October 20, 2017, post-market, Antares announced receipt of a Complete Response Letter ("CRL") from the FDA regarding the NDA for Xyosted, "indicat[ing] that the FDA cannot approve the NDA in its present form." The Company stated, in part that "the FDA is concerned that XYOSTED could cause a clinically meaningful increase in blood pressure" and also "raised a concern regarding the occurrence of depression and suicidality."

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

© Accesswire 2017
All news about ANTARES PHARMA, INC.
02/24ANTARES PHARMA  : to Present at Two Upcoming Investor Conferences
02/23ANTARES PHARMA  : to Report Fourth Quarter and Full-Year 2020 Financial and Oper..
02/19INSIDER TRENDS : Insider at Antares Pharma Awarded Stock Uses Portion to Pay Tax..
02/17Antares Pharma to Participate in the SVB Leerink 10th Annual Virtual Global H..
02/02PRESS RELEASE : Scenic Biotech BV: Scenic Biotech Appoints Dr. Philippe Dro as I..
01/11ANTARES PHARMA  : Boosts Full-Year 2020 Revenue Guidance
01/11ANTARES PHARMA, INC.  : Results of Operations and Financial Condition, Regulatio..
01/11ANTARES PHARMA  : Announces Full-Year 2021 Revenue Guidance of $175-200 Million
2020Antares Pharma to Participate in the Piper Sandler 32nd Annual Virtual Health..
2020Antares Pharma to Participate in the Piper Sandler 32nd Annual Virtual Health..
More news
Financials (USD)
Sales 2020 147 M - -
Net income 2020 10,8 M - -
Net Debt 2020 - - -
P/E ratio 2020 69,2x
Yield 2020 -
Capitalization 750 M 750 M -
Capi. / Sales 2020 5,09x
Capi. / Sales 2021 4,06x
Nbr of Employees 178
Free-Float 92,5%
Duration : Period :
Antares Pharma, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ANTARES PHARMA, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 6
Average target price 6,42 $
Last Close Price 4,50 $
Spread / Highest target 77,8%
Spread / Average Target 42,6%
Spread / Lowest Target 0,00%
EPS Revisions
Managers and Directors
Robert F. Apple President, Chief Executive Officer & Director
Fred M. Powell CFO, Principal Accounting Officer & Executive VP
Leonard S. Jacob Chairman
Jonathan S. Jaffe Vice President-Clinical & Medical Affairs
Patrick Madsen Senior Vice President-Operations
Sector and Competitors
1st jan.Capitalization (M$)
MEDTRONIC PLC-0.15%157 614